And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still taking shape. However, we do foresee several naps in our future, if only to recover from promenading with the official mascots. We also hope to catch up on our reading and hold another listening party with Mrs. Pharmalot. The rotation will likely include this, this, this, this and this. And what about you? This is a fine time to enjoy the great outdoors — a walk in the woods, a stroll along city streets, or a day at the shore may be in order. You could plan a summer getaway or tidy up around the castle. Or reach out to someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …
Social media is displacing physicians as the trusted authorities on whether patients should take weight loss medicines, The Wall Street Journal explains. People are not only deciding to take a weight loss drug based on posts by friends and influencers but sometimes also skipping their doctor to go with one mentioned online. The virtual word-of-mouth can come across as authentic and accessible. People say they appreciate the tips and support they get from other online users. But many influencers and friends on social media play up all the pounds a person lost while playing down side effects that can be nasty, such as painful headaches and bouts of vomiting. Some omit risks altogether.
Biocon is developing its own version of Novo Nordisk’s Wegovy and is prepared to conduct a clinical trial next year if needed, Reuters reports. The company, which derives most of its revenue from foreign markets such as the U.S., aims to first launch generic versions of the weight loss drugs in emerging markets such as Brazil, Mexico, and Saudi Arabia. Semaglutide will lose patent protection in those countries in 2026, and Biocon is talking to local manufacturers regarding partnerships to ensure supply. Biocon will first try to get a waiver on clinical trials from Indian regulators and instead submit bioequivalence studies showing that its version has an equivalent effect as semaglutide.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect